Nusano
  • Company
    • Leadership
    • Mission & Values
    • West Valley City
    • Contact Us
  • Technology
  • Life Sciences
    • Medical Isotopes
    • Request Quote
    • R&D Collaboration
    • Advisory Board
    • About Nuclear Med
  • Energy
    • HALEU
    • Nuclear Fuel Cycle
  • Industrial
  • Batteries
  • News
    • Press Releases
    • Video
    • Podcast
  • Careers
    • Current Openings
    • Life in Utah
Select Page
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

by Scott Larrivee | Jun 19, 2025 | News

Alpha-emitting radioisotope expected to play an essential role in next-generation targeted cancer therapies  DURHAM, N.C. and WEST VALLEY CITY, Utah – June 19, 2025 – dGenThera, Inc., a biotechnology company pioneering theranostic molecular pairs, and Nusano, a...
Talk Radioisotopes: Milton Lönnroth, Co-Founder and CEO, Atley Solutions

Talk Radioisotopes: Milton Lönnroth, Co-Founder and CEO, Atley Solutions

by Scott Larrivee | May 16, 2025 | Podcast

In this episode, Milton Lönnroth, Co-Founder and CEO, shares how Atley Solutions is changing the game for astatine-211, a promising isotope in cancer therapy. Atley supports radiopharmaceutical companies and researchers by enabling the scalable production and labeling...
Registration for 2025 World Astatine Community Meeting Now Open

Registration for 2025 World Astatine Community Meeting Now Open

by Scott Larrivee | May 12, 2025 | News

Radiopharmaceutical experts and researchers to gather June 19-20 in New Orleans NEW ORLEANS – May 12, 2025 – The first-ever U.S.-based meeting of the World Astatine Community will take place June 19-20, 2025 at the Sheraton in downtown New Orleans. The event will...
dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply

Nusano and Atley Solutions in Collaboration to Accelerate Astatine-211 Development

by Scott Larrivee | Jan 16, 2025 | News

Nusano isotope production to deliver breakthrough, 100X increase in global At-211 supply, and Atley’s radiopharmaceutical manufacturing technology to enable scalable At-211 radiopharmaceutical supply VALENCIA, Calif. and GOTHENBURG, Sweden – Jan. 16, 2025 – Nusano, a...
Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress

Nusano to Present Isotope Production Capabilities and Commercialization Plans at 7th Theranostics World Congress

by Scott Larrivee | Mar 20, 2024 | News

Presentation materials  Download VALENCIA, Calif. – March 20, 2024 – Nusano, a physics company transforming the production of medical radioisotopes, will present at the 7th Theranostics World Congress taking place March 22-24, 2024, in Santiago, Chile. Greg Moffitt,...
« Older Entries

Recent Posts

  • Talk Radioisotopes: Paul Schrimpf, Proprietor & Entrepreneur, Cyrall
  • Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
  • Nusano CEO Chris Lowe on Connor Group Podcast
  • dGenThera and Nusano Sign Letter of Intent for Astatine‑211 Supply
  • Ratio Therapeutics and Nusano Enter Long-Term, Multi-Isotope Supply Agreement to Boost Production of Cancer Radiopharmaceuticals

Recent Comments

No comments to show.
Nusano
Supplying the fight against cancer & enabling life-changing innovations
  • Follow
  • Follow
  • Follow
Company
about us
Leadership
Contact us
technology

The Nusano Platform
R&D Collaboration

Resources
News
Careers
Suppliers
© 2025 Nusano | Web design
Privacy Policy – Terms of Service